Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths

Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a precaution

We're reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more

Today's pharma news covers a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and a organ transplant first

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Novartis Suspends Eight CAR-T Studies After Patient Deaths Trigger Safety Review

As reported in the European Medical Journal, Novartis has paused eight clinical studies evaluating its experimental CAR-T cell therapy, known as rap-cell, after three trial participants died following severe immune-related complications. The decision has prompted a broad safety review as the company works with independent experts and health authorities to better understand the events. The […]

Novartis halts CAR-T therapy trials after patient deaths

Three patients have died due to a severe autoimmune reaction following dosing with a CAR-T therapy.